Cargando…
Plasmodium falciparum infection coinciding with the malaria vaccine candidate BK-SE36 administration interferes with the immune responses in Burkinabe children
BACKGROUND: A vaccine targeting the erythrocyte stages of Plasmodium falciparum could play a role in preventing clinical disease. BK-SE36 is a promising malaria vaccine candidate that has shown a good safety profile and immunological responses during field evaluations. It was observed that repeated...
Autores principales: | Tiono, Alfred B., Palacpac, Nirianne Marie Q., Bougouma, Edith Christiane, Nebie, Issa, Ouédraogo, Alphonse, Houard, Sophie, Arisue, Nobuko, D’Alessio, Flavia, Horii, Toshihiro, Sirima, Sodiomon B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10040972/ https://www.ncbi.nlm.nih.gov/pubmed/36993981 http://dx.doi.org/10.3389/fimmu.2023.1119820 |
Ejemplares similares
-
Safety and immunogenicity of BK-SE36 in a blinded, randomized, controlled, age de-escalating phase Ib clinical trial in Burkinabe children
por: Bougouma, Edith Christiane, et al.
Publicado: (2022) -
Safety and immunogenicity of BK-SE36/CpG malaria vaccine in healthy Burkinabe adults and children: a phase 1b randomised, controlled, double-blinded, age de-escalation trial
por: Ouédraogo, Alphonse, et al.
Publicado: (2023) -
African-specific polymorphisms in Plasmodium falciparum serine repeat antigen 5 in Uganda and Burkina Faso clinical samples do not interfere with antibody response to BK-SE36 vaccination
por: Arisue, Nobuko, et al.
Publicado: (2022) -
Safety and Immunogenicity of the Malaria Vaccine Candidate MSP3 Long Synthetic Peptide in 12–24 Months-Old Burkinabe Children
por: Sirima, Sodiomon B., et al.
Publicado: (2009) -
Correction: Safety and Immunogenicity of the Malaria Vaccine Candidate MSP3 Long Synthetic Peptide in 12–24 Months-Old Burkinabe Children
por: Sirima, Sodiomon B., et al.
Publicado: (2010)